{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:54:14Z","timestamp":1791258854027,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["RFA-FD-21-004"],"award-info":[{"award-number":["RFA-FD-21-004"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["UG3 FD006794-01"],"award-info":[{"award-number":["UG3 FD006794-01"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["UG3\/UH3 FD007308"],"award-info":[{"award-number":["UG3\/UH3 FD007308"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009210","name":"Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jval.2026.04.012","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:03:17Z","timestamp":1778889797000},"page":"1769-1780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["How Much Change Is Meaningful in Global Impression Anchors? Evidence From 5 Rare Diseases"],"prefix":"10.1016","volume":"29","author":[{"given":"Courtney","family":"Hurt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Kuharic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloise","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Eremenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Perschon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Shaunfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Devin","family":"Peipert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jval.2026.04.012_bib1","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","article-title":"Rare disease terminology and definitions-A systematic global review: report of the ISPOR rare disease Special Interest Group","volume":"18","author":"Richter","year":"2015","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.jval.2026.04.012_bib2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2019.0290","article-title":"The orphan drug act revisited","volume":"321","author":"Thomas","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jval.2026.04.012_bib4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/ajmg.a.38413","article-title":"Challenges of developing and conducting clinical trials in rare disorders","volume":"176","author":"Kempf","year":"2018","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.jval.2026.04.012_bib5","series-title":"Guidance for Industry, FDA Staff, and Other Stakeholders (U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), and Center for Devices and Radiological Health (CDRH))","year":"2023"},{"issue":"1","key":"10.1016\/j.jval.2026.04.012_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/MLR.0000000000000273","article-title":"Patient-focused drug development: a new direction for collaboration","volume":"53","author":"Perfetto","year":"2015","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2026.04.012_bib7","article-title":"Advancing rare disease measurement through the Rare Disease Clinical Outcome Assessment Consortium","volume":"5","author":"Knoble","year":"2024","journal-title":"Ther Adv Rare Dis"},{"issue":"4","key":"10.1016\/j.jval.2026.04.012_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status: ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"issue":"2","key":"10.1016\/j.jval.2026.04.012_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/erp.11.9","article-title":"A point of minimal important difference (MID): a critique of terminology and methods","volume":"11","author":"King","year":"2011","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.jval.2026.04.012_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11136-017-1616-3","article-title":"Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores","volume":"27","author":"Coon","year":"2018","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.jval.2026.04.012_bib12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.jval.2026.04.012_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/2168479015622667","article-title":"Interpreting change in scores on patient-reported outcome instruments","volume":"50","author":"Coon","year":"2016","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"10.1016\/j.jval.2026.04.012_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41687-019-0100-y","article-title":"An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments","volume":"3","author":"Staunton","year":"2019","journal-title":"J Patient Rep Outcomes"},{"issue":"2","key":"10.1016\/j.jval.2026.04.012_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1586\/erp.11.12","article-title":"Interpreting patient-reported outcome results: US FDA guidance and emerging methods","volume":"11","author":"McLeod","year":"2011","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"10.1016\/j.jval.2026.04.012_bib16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s12325-019-00920-x","article-title":"The case for the use of patient and caregiver perception of change assessments in rare disease clinical trials: a methodologic overview","volume":"36","author":"Contesse","year":"2019","journal-title":"Adv Ther"},{"issue":"5 Suppl 1","key":"10.1016\/j.jval.2026.04.012_bib17","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/01.mlr.0000254567.79743.e2","article-title":"Evaluation of item candidates: the PROMIS qualitative item review","volume":"45","author":"DeWalt","year":"2007","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2026.04.012_bib18","series-title":"Embedded cognitive debriefing to assess content validity of physical function performance outcome measures in a multi-condition validation study","author":"Hurt","year":"2025"},{"issue":"9384","key":"10.1016\/j.jval.2026.04.012_bib19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","article-title":"Nephrotic syndrome in childhood","volume":"362","author":"Eddy","year":"2003","journal-title":"Lancet"},{"issue":"7654","key":"10.1016\/j.jval.2026.04.012_bib20","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/bmj.39576.709711.80","article-title":"Nephrotic syndrome in adults","volume":"336","author":"Hull","year":"2008","journal-title":"Bmj"},{"issue":"B","key":"10.1016\/j.jval.2026.04.012_bib21","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3889\/oamjms.2021.6601","article-title":"Health-related quality of life difference between early diagnosed and finished therapy of nephrotic syndrome in children","volume":"9","author":"Ruslie","year":"2021","journal-title":"Open Access Maced J Med Sci"},{"issue":"6","key":"10.1016\/j.jval.2026.04.012_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100826","article-title":"A review of focal segmental glomerulosclerosis classification with a focus on genetic associations","volume":"6","author":"Bonilla","year":"2024","journal-title":"Kidney Med"},{"issue":"3","key":"10.1016\/j.jval.2026.04.012_bib23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2215\/CJN.04321007","article-title":"Idiopathic membranous nephropathy: diagnosis and treatment","volume":"3","author":"Fervenza","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.jval.2026.04.012_bib24","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nrneph.2016.147","article-title":"Minimal change disease and idiopathic FSGS: manifestations of the same disease","volume":"12","author":"Maas","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"10.1016\/j.jval.2026.04.012_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019993","article-title":"Can rapid approaches to qualitative analysis deliver timely, valid findings to clinical leaders? A mixed methods study comparing rapid and thematic analysis","volume":"8","author":"Taylor","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jval.2026.04.012_bib26","first-page":"1","article-title":"The Preparing a clinical outcome assessment set for nephrotic syndrome (Prepare-NS) Project: a Core Set of Clinical Outcome Assessments and Endpoints for nephrotic syndrome Related to Rare Kidney Disease","volume":"33","author":"Peipert","year":"2024","journal-title":"Qual Life Res"},{"issue":"Suppl 1","key":"10.1016\/j.jval.2026.04.012_bib27","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/MLR.0000000000001087","article-title":"Pro-bookmarking to estimate clinical thresholds for patient-reported symptoms and function","volume":"57","author":"Reeve","year":"2019","journal-title":"Med Care"},{"issue":"10","key":"10.1016\/j.jval.2026.04.012_bib28","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1007\/s11136-023-03439-5","article-title":"Using bookmarking methods with orthopedic clinicians and patients with fractures produces score interpretation labels for patient-reported outcome measures","volume":"32","author":"Rothrock","year":"2023","journal-title":"Qual Life Res"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526024253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526024253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:46:02Z","timestamp":1791258362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526024253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1098301526024253"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.04.012","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How Much Change Is Meaningful in Global Impression Anchors? Evidence From 5 Rare Diseases","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}